Testicular cancer study tests stronger chemo to slash relapse risk
NCT ID NCT02341989
First seen Jan 05, 2026 · Last updated Jun 11, 2026 · Updated 30 times
Summary
This study compares two chemotherapy approaches for men with stage I seminoma testicular cancer who have a higher risk of the cancer coming back. One group gets a single course of carboplatin, the current standard, while the other gets a stronger combination of three drugs (BEP). The goal is to see if BEP lowers the relapse rate more effectively and to check how each treatment affects quality of life and side effects. About 348 men aged 18 to 59 with tumors larger than 4 cm or invasion of the rete testis are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEMINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institutt for kreftforskning og molekylær medisin, St Olavs Hospital
Trondheim, Norway
-
St. Olavs University hospital HF
Trondheim, Norway
Conditions
Explore the condition pages connected to this study.